Bisphenol AP is anti-estrogenic and may cause adverse effects at low doses relevant to human exposure
2018
Xiao, Xuan | Li, Junyu | Yu, Tong | Zhou, Lei | Fan, Xiaolin | Xiao, Han | Wang, Yue | Yang, Lei | Lv, Junhui | Jia, Xiaojing | Zhang, Zhaobin
A recent increase in the use of bisphenol A (BPA) alternatives to manufacture plastics has led to safety concerns. Here, we evaluated the estrogenic and anti-estrogenic activities of bisphenol AP (BPAP), a poorly studied BPA alternative, using in vitro, in vivo and in silico tools. BPAP exhibited weak estrogenicity but strong anti-estrogenicity (IC₅₀ = 2.35 μM) in a GeneBLAzer™ β-lactamase reporter gene assay. BPAP, when administered alone or in combination with E₂ (50 μg kg⁻¹ bw d⁻¹) for 3 d, significantly decreased the uterine weights of post-weaning CD-1 mice at doses of 10 mg kg⁻¹ bw d⁻¹ and higher. When administered alone to prepubertal CD-1 mice for 10 d, BPAP significantly decreased the uterine weights at doses of 80 μg kg⁻¹ bw d⁻¹ and higher. Toxicogenomic analysis showed that BPAP regulated an opposite patterns of gene expression than that of E₂ in mouse uteri. In a glucose tolerance test using male mice, BPAP was found to disrupt the blood glucose homeostasis at low doses relevant to human exposure (1 and 100 μg kg⁻¹ bw d⁻¹). Our results suggest that BPAP should be of great concern which might affect the sexual development in immature feminine and disrupt the blood glucose homeostasis at very low doses.
Показать больше [+] Меньше [-]Ключевые слова АГРОВОК
Библиографическая информация
Эту запись предоставил National Agricultural Library
